The GLP-1 Catalyst: Transforming Health Care Markets

About

The advent of GLP-1 receptor agonists is not just a significant milestone in diabetes and obesity treatment; it presents opportunity for systemic change in disease prevention and management as well as overall health economics. But what does that mean for the health care industry as a whole?

Join us for a forward-looking conversation exploring the transformative ripple effects of GLP-1s. A panel of multidisciplinary experts will discuss how GLP-1 treatments can alter patient care pathways, reduce long-term health care costs, and improve patient outcomes on a macro scale, while at the same time impacting payer strategies, delivery models, and patient engagement.

Featured Speakers

• Guy D’Andrea, executive director, Catalyst for Payment Reform
• Gary Foster, Ph.D., chief scientific officer, WeightWatchers
• Susan Nemetz, founder and CEO of Corval; founder and CEO of The NemetzGroup
• Courtney Younglove, M.D., founder & medical director, Heartland Weight Loss and WellMi and chief medical director, Journeys Metabolic
• Rita Glaze-Rowe, president, transformative healthcare markets, Real Chemistry (moderator)
• Rick Berke, co-founder and executive editor, STAT (opening remarks)

Register Now

More on Open Doors

Open Doors are convenings hosted by STAT in collaboration with leading industry organizations. Collaborators on Open Doors provide a unique opportunity for STAT readers to experience their brand, learn from their insights, and understand the cutting-edge work they are doing in biotech, pharma, and the life sciences.

This specific Open Doors event is hosted by STAT in collaboration with Real Chemistry. It is important to note that Real Chemistry is solely responsible for curating the program for this event, and STAT’s editorial team has not played a role in crafting content or selecting speakers.